April 21, 2014 12:58 AM ET

Biotechnology

Company Overview of Kindred Biosciences, Inc.

Company Overview

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its primary small molecule product candidates include CereKin, an oral interleukin-1 beta inhibitor for osteoarthritis pain and inflammation in dogs; AtoKin, a beef-flavored formulation of fexofenadine for atopic dermatitis in dogs; and SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-007, an inhibitor of Bruton’s t...

1499 Bayshore Highway

Suite 226

Burlingame, CA 94010

United States

Founded in 2012

12 Employees

Phone:

650-701-7901

Key Executives for Kindred Biosciences, Inc.

Co-Founder
Age: 46
Total Annual Compensation: $486.3K
Co-Founder
Age: 46
Total Annual Compensation: $214.1K
Chief Scientific Officer and Head of Research & Development
Age: 61
Total Annual Compensation: $95.3K
Compensation as of Fiscal Year 2013.

Kindred Biosciences, Inc. Key Developments

Kindred Eyes Acquisitions

Kindred Biosciences, Inc. (NasdaqCM:KIN) announced the closing of its public offering of 3,450,000 shares of its common stock, including 450,000 shares sold pursuant to the exercise in full by the underwriters of their over-allotment option, at a public offering price of $18.00 per share. In a release on April 8, 2014 Kindrednoted that it estimates net proceeds from the offering to be approximately $58.1 million. Kindred Bio intends to use the net proceeds of the offering for potential acquisitions of additional product candidates or other complementary assets or businesses, to accelerate and expand the research and development of its current product candidates, and for general corporate and working capital purposes.

Kindred Bio Mulls Acquisitions

Kindred Biosciences, Inc. (NasdaqCM:KIN) is seeking acquisition opportunities. Kindred Bio announced the pricing of its public offering of 3 million shares of its common stock at a public offering price of $18 per share, for a total offering amount of $54 million. Kindred Bio intends to use the net proceeds of the offering for potential acquisitions of additional product candidates or other complementary assets or businesses, to accelerate and expand the research and development of its current product candidates and for general corporate and working capital purposes.

Kindred Biosciences, Inc.(NasdaqCM:KIN) added to Russell 2000 Index

Kindred Biosciences, Inc. will be added to the Russell 2000 Index.

Similar Private Companies By Industry

Company Name Region
Warner Instruments Corporation United States
BioSeparations, Inc. United States
Linkage Biosciences, Inc. United States
BIO Wellness, Inc. United States
Genset Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 31, 2013
--
Private Placement
June 30, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kindred Biosciences, Inc., please visit www.kindredbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.